Dry Eye Disease: Current and Emerging Novel Tear Stimulating Therapies for Improved Outcomes

Complimentary

Live Virtual Webinar:
Saturday, April 12, 2025, at 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT

Categories: , , , , , , , , , ,
Close-up of a human eye with digital elements symbolizing eye disease research.

Take Me to the Event Registration

Program Description

Click to Go to the Event Registration

This program will provide up-to-date, evidence-based information on DED, evaluations, and emerging therapies. The activity will focus on:

Pathophysiology of DED – The pathogenesis of MGD and DED can be described as a ‘vicious circle’; the underlying pathophysiological mechanisms of DED and MGD interact, resulting in a ‘double vicious circle’

  • The vicious circle of DED
  • Dual “Vicious Circle” of DED and MGD
  • Factors Contributing to DED
    • Preservatives in topicals contribute to DED
    • DED in patients after refractive or cataract surgery
    • DED in postmenopausal women
    • DED in patients with autoimmune disorders

Available Treatment Options for MGD-Associated DED – Treatment for MGD-associated DED encompasses a wide range of approaches, such as:

  • Preservative-free Artificial Tears,
  • Warming and Eyelid Compression,
  • Thermal Pulsation,
  • LipiFlow Thermal Pulsation System,
  • Intense Pulsed Light (IPL) Therapy,
  • Topical and oral Azithromycin,
  • Intraductal probing,
  • Hormone Replacement Therapy (HRT) to alleviate DED in menopausal women,
  • Topical anti-inflammatory therapies, such as tacrolimus and cyclosporin A for DED in patients with autoimmune diseases

Novel Tear Stimulating Therapies

New treatment options for DED – Several pharmacologic agents with novel mechanisms of action for treating DED are under development.

  • Varenicline nasal spray
  • Perfluorohexyloctane ophthalmic solution (Miebo®)
  • Lifitegrast
  • Reproxalap
  • Water-free topical cyclosporine, 0.1% and 0.5%
  • AZR-MD-001 (selenium sulfide ophthalmic ointment)
  • NOV03 (perfluorohexyloctane)
  • Lotilaner (TP-03)

Agenda

• Discuss the pathophysiology and factors contributing to DED such as preservatives in topicals, refractive or cataract surgery, menopause, and autoimmune diseases – Neal Guymon, OD

• Discuss the real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED – Eric D. Donnenfeld, MD

Intended Audience

Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED).

Commercial Supporter

Supported by an unrestricted educational grant from Oyster Point

Learning Objectives

  • Summarize the pathophysiology and factors contributing to DED, such as preservatives in topicals, refractive or cataract surgery, menopause, and autoimmune diseases
  • Assess real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED

Accredited Providers

Amedco and MedNet have collaborated to design and execute this activity.

      

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Optometrists Credit

This activity, COPE course 97133-TD, is accredited by COPE for continuing education for optometrists. COPE Activity ID#130386.

MedNet designates this activity for a maximum of 1.25 COPE credits.

Additional Credit Information

Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours.

Disclosures of Relationships with Ineligible Companies Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

Planners’ and Managers’ Disclosures

All relevant relationships have been reviewed and mitigated.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Neal Guymon, OD
Optometrist
Summit EyeCare
Idaho Falls, ID

Eric D. Donnefeld, MD
Clinical Professor of Ophthalmology
New York University Langone Medical Center
Ophthalmic Consultants of Long Island
New York, NY

Instructions/Technical Requirements

Hardware: An internet-enabled computer, smartphone, tablet, or other mobile device with audio and internet capabilities.

Software: Installation of software like Zoom may be necessary.

    Cost

    There are no fees for participating and receiving CME and COPE credit for this activity.

    Contact

    Brian Waggoner
    Program Manager
    MedNet
    brianw@mmhus.net

    EVENT Summary

    Dates

    Saturday, April 12, 2025, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT

    Location

    Virtual

    Target Audience

    Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED)

    Format

    Zoom Webinar

    Credits

    1.25 / AMA PRA Category 1 Credit(s)TM
    1.25 / COPE CE Credits

    Cost

    Complimentary

    Related products